EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME

被引：0
|
作者：
Lee, Dae Wook [1 ]
Monteiro, Pedro [2 ]
Clark, Douglas [3 ]
Hantel, Stefan [3 ]
Woerle, Hans J. [3 ]
Inzucchi, Silvio E. [4 ]
Fitchett, David [5 ]
机构：
[1] Boehringer Ingelheim Korea, Med Affairs, Dept Med Affairs Metab, Seoul, South Korea
[2] Univ Coimbra, Dept Coimbra Hosp, Coimbra, Portugal
[3] Boehringer Ingelheim Pharma GmbH & Co KG, GmbH & Co KG, Ingelheim, Germany
[4] Yale Univ, Sch Med, Dept Endocrinol, New Haven, CT 06520 USA
[5] Univ Toronto, St Michaels Hosp, Dept Cardiol, Toronto, ON, Canada
来源：
JOURNAL OF HYPERTENSION | 2016年 / 34卷
关键词：
D O I：
10.1097/01.hjh.0000501423.64635.bd
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
LBPS 02-52
引用
收藏
页码：E520 / E520
页数：1
相关论文
共 50 条
  • [21] MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL
    Jardine, M.
    Wanner, C.
    Nangaku, M.
    Kraus, B.
    Zinman, B.
    Mattheus, M.
    Hantel, S.
    Schumacher, M.
    Ohneberg, K.
    Schmoor, C.
    Inzucchi, S. E.
    NEPHROLOGY, 2021, 26 : 19 - 19
  • [22] Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME
    Pellicori, Pierpaolo
    Ofstad, Anne Pernille
    Fitchett, David
    Zeller, Cordula
    Wanner, Christoph
    George, Jyothis
    Zinman, Bernard
    Brueckmann, Martina
    Lindenfeld, JoAnn
    ESC HEART FAILURE, 2020, 7 (06): : 3401 - 3407
  • [23] Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial
    Boehm, Michael
    Slawik, Jonathan
    Brueckmann, Martina
    Mattheus, Michaela
    George, Jyothis T.
    Ofstad, Anne Pernille
    Inzucchi, Silvio E.
    Fitchett, David
    Anker, Stefan D.
    Marx, Nikolaus
    Wanner, Christoph
    Zinman, Bernard
    Verma, Subodh
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (01) : 126 - 135
  • [24] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
  • [25] Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
    Xingjuan Shi
    Subodh Verma
    Junghwa Yun
    Koroboshka Brand-Arzamendi
    Krishna K. Singh
    Xiangdong Liu
    Ankit Garg
    Adrian Quan
    Xiao-Yan Wen
    Molecular and Cellular Biochemistry, 2017, 433 : 97 - 102
  • [26] Empagliflozin improves renal outcomes in patients with or without heart failure at baseline - insights from the EMPA-REG OUTCOME trial
    Butler, J. Javed
    Zannad, F.
    Fitchett, D.
    Zinman, B.
    Koitka-Weber, A.
    Von Eynatten, M.
    Hehnke, U.
    George, J.
    Brueckmann, M.
    Cheung, A. K.
    Wanner, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 380 - 381
  • [27] Reduced progression of kidney disease with empagliflozin: results from EMPA-REG OUTCOME
    Wanner, C.
    Inzucchi, S.
    Lachin, J. M.
    Fitchett, D.
    von Eynatten, M.
    Mattheus, M.
    Johansen, O. E.
    Woerle, H. J.
    Broedl, U. C.
    Zinman, B.
    DIABETIC MEDICINE, 2017, 34 : 80 - 81
  • [28] Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
    Shi, Xingjuan
    Verma, Subodh
    Yun, Junghwa
    Brand-Arzamendi, Koroboshka
    Singh, Krishna K.
    Liu, Xiangdong
    Garg, Ankit
    Quan, Adrian
    Wen, Xiao-Yan
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2017, 433 (1-2) : 97 - 102
  • [29] Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
    Ampudia-Blasco, Francisco Javier
    Romera, Irene
    Arino, Bernat
    Gomis, Ramon
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2017, 10 : 23 - 26
  • [30] Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    Zwiener, Isabella
    Kaspers, Stefan
    Clark, Douglas
    George, Jyothis T.
    Zinman, Bernard
    DIABETES CARE, 2019, 42 (04) : E53 - E55
12345